Loading…
← CockpitCompetitor Analysis › 688621.SS Beijing Sun-Novo Pharmaceutical Research Co. Ltd. Class AOpen in the cockpit ↗

Beijing Sun-Novo Pharmaceutical Research Co. Ltd. Class A688621.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Beijing-based pharmaceutical research and manufacturing company selling drugs in China.

Momentum neutral 57
Mkt cap
$849M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$15.6M
20-day average traded
Fwd P/E
29.0×
forward earnings
ROIC−WACC
-5.9 pp
WACC 7.8%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · CNYCN¥51.80
1D-1.3%
1W-6.4%
1M-13.7%
3M-21.6%
6M-7.8%
YTD-16.6%
1Y-8.1%
ATR %6.2%
52w lowhigh35.8% off high

What Beijing Sun-Novo Pharmaceutical Research does

Beijing-based pharmaceutical research and manufacturing company selling drugs in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics/specialty

Moat: none

Headquarters: Beijing, China · Employees: 1,335

Beijing Sun-Novo Pharmaceutical Research at a glance

Size Beijing Sun-Novo Pharmaceutical Research (688621.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $849M, the 2480th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥51.80 on 18 Nov 2026.

Performance Over six months the shares fell 7.8%, against -18.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 19 in its peer set.

Growth Revenue fell 0.6% over the last twelve months (peer median +6.6%); the operating margin is -1.8% (peer median 2.7%).

Valuation It trades at 29.0× forward earnings against a peer median of 17.7× (3rd most expensive of 9).

Capital Return on invested capital runs 5.9 points below its cost of capital (7.8% WACC).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026688621.SS 90Peer median 79
Six months, rebased to 100: Beijing Sun-Novo Pharmaceutical Research against the median of its 20 peers (local-currency closes).

Beijing Sun-Novo Pharmaceutical Research financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.01BCN¥1.22BCN¥1.08BCN¥931MCN¥676M
Revenue growth—+13%+16%+38%—
Gross profitCN¥550MCN¥634MCN¥512MCN¥499MCN¥358M
EBITDAn/aCN¥277MCN¥241MCN¥255MCN¥208M
Net incomeCN¥6.04MCN¥204MCN¥177MCN¥185MCN¥156M
Free cash flow-CN¥161MCN¥53.5MCN¥4.39MCN¥21.2MCN¥2.71M
Capital expenditureCN¥50.6MCN¥42.4MCN¥30.5MCN¥73.0MCN¥104M
Total debtCN¥713MCN¥613MCN¥457MCN¥448MCN¥259M

Quarterly statements and history in the cockpit →

Beijing Sun-Novo Pharmaceutical Research competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%688176086450069620CRVS4521600771006120PHARM300267SANOFICONR0008136032290020826078COLL000597AKTSSUVEN688621.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Sun-Novo Pharmaceutical Research is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×0864500696204521600771PHARMSANOFICONR6078COLL688621.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Sun-Novo Pharmaceutical Research is the large dot.

Beijing Sun-Novo Pharmaceutical Research competitors and peer comparison

How Beijing Sun-Novo Pharmaceutical Research compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Sun-Novo Pharmaceutical Research against its 20 peers (data as of 18 Nov 2026)
Measure688621.SSPeer medianRank in peer set
1-month return-13.7%-7.7%6th lowest of 21
6-month return-7.8%-18.1%6th highest of 19
Distance from 52-week high-35.8%-40.2%9th highest of 21
Revenue growth (TTM)-0.6%+6.6%6th lowest of 19
Operating margin-1.8%2.7%8th lowest of 19
Forward P/E29.0×17.7×3rd most expensive of 9
ROIC minus cost of capital-5.9 pp-2.3 pp5th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%n/an/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%14.0×-4.2%+10.6%
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%9.0×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%21.4×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%38.3×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%n/an/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%34.9×2.4%+12.4%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a

Questions

Which companies are Beijing Sun-Novo Pharmaceutical Research's closest peers?
The cockpit's peer set: Jiangsu Yahong Meditech (688176.SS), DongKook Pharmaceutical (086450.KS), Daewoong Pharm (069620.KS), Corvus Pharmaceuticals (CRVS), Kaken Pharmaceutical (4521.T), City Therapeutics (CTY), GuangYuYuan Chinese Herbal Medicine (600771.SS), SK Discovery (006120.KS).
Is Beijing Sun-Novo Pharmaceutical Research expensive compared with its peers?
On forward p/e it trades at 29.0× against a peer median of 17.7×, 3rd most expensive of 9 in its peer set.
How has Beijing Sun-Novo Pharmaceutical Research stock performed?
Over six months to 18 Nov 2026 the shares returned -7.8% against -18.1% for the median peer; over one year -8.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.